Loading clinical trials...
Loading clinical trials...
A Phase I Study of ExoFlo, an Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease
Conditions
Interventions
ExoFlo
Locations
2
United States
Direct Biologics Investigational Site
Los Angeles, California, United States
Direct Biologics Investigational Site
New York, New York, United States
Start Date
January 23, 2023
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2024
Last Updated
February 11, 2025
NCT05421455
NCT06226883
NCT05986136
NCT07245394
NCT07089420
NCT05698745
Lead Sponsor
Direct Biologics, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions